(Q38837294)

6 September 2017

1 reference

title

Further understanding of the immunopathology of multiple sclerosis: impact on future treatments (English)

1 reference

6 September 2017

1 reference

Vikram Bhise

1

1 reference

PubMed ID

27191526

6 September 2017

Suhayl Dhib-Jalbut

series ordinal

2

1 reference

6 September 2017

18 May 2016

1 reference

Expert Review of Clinical Immunology

6 September 2017

1 reference

6 September 2017

12

1 reference

6 September 2017

10

1 reference

6 September 2017

1069-1089

1 reference

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

6 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Pathology and disease mechanisms in different stages of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The immune pathogenesis of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The British Isles survey of multiple sclerosis in twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The genetics of multiple sclerosis: an up-to-date review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Risk alleles for multiple sclerosis identified by a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Epigenetic mechanisms in multiple sclerosis: implications for pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Gene-environment interaction in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Multiple sclerosis: molecular mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Pathologic heterogeneity persists in early active multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Inflammatory cortical demyelination in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Disease-specific molecular events in cortical multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Self-tolerance in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Regulatory T cell proliferative potential is impaired in human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Specific peripheral B cell tolerance defects in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Increased CD8+ T cell responses to apoptotic T cell-associated antigens in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Differential roles of microglia and monocytes in the inflamed central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The evidence for a role of B cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Potassium channel KIR4.1 as an immune target in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Mitochondrial defects in acute multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Mitochondrial changes within axons in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Enhanced number and activity of mitochondria in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Mitochondrial immobilization mediated by syntaphilin facilitates survival of demyelinated axons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Immunomodulatory effects of Vitamin D in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Monthly ambient sunlight, infections and relapse rates in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Vitamin D as an early predictor of multiple sclerosis activity and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Vitamin D-binding protein controls T cell responses to vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Vitamin D improves cognitive function and modulates Th17/T reg cell balance after hepatectomy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Genomic binding sites and biological effects of the vitamin D--VDR complex in multiple sclerosis [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Association of innate immune activation with latent Epstein-Barr virus in active MS lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Radioactive in situ hybridization for Epstein-Barr virus-encoded small RNA supports presence of Epstein-Barr virus in the multiple sclerosis brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A functional and structural basis for TCR cross-reactivity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Environmental risk factors for multiple sclerosis. Part I: The role of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Common viruses associated with lower pediatric multiple sclerosis risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Smoking and multiple sclerosis susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Smoking as a risk factor for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Smoking and multiple sclerosis: evidence for latitudinal and temporal variation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Effects of tobacco smoke on immunity, inflammation and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Cigarette smoking and inflammation: cellular and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

T cells become licensed in the lung to enter the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Role of "Western diet" in inflammatory autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Body size and risk of MS in two cohorts of US women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Childhood body mass index and multiple sclerosis risk: a long-term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Obesity during childhood and adolescence increases susceptibility to multiple sclerosis after accounting for established genetic and environmental risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Sodium intake is associated with increased disease activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Immune response after experimental allergic encephalomyelitis in rats subjected to calorie restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

High fat diet exacerbates neuroinflammation in an animal model of multiple sclerosis by activation of the Renin Angiotensin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Obesity predisposes to Th17 bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Interaction between adolescent obesity and HLA risk genes in the etiology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Role of the microbiota in immunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Gut commensalism, cytokines, and central nervous system demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A commensal bacterial product elicits and modulates migratory capacity of CD39(+) CD4 T regulatory subsets in the suppression of neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Association between parasite infection and immune responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Intestinal barrier dysfunction develops at the onset of experimental autoimmune encephalomyelitis, and can be induced by adoptive transfer of auto-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Immunology of relapse and remission in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Involvement of CD8(+) T Cells in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The risk of relapses in multiple sclerosis during systemic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Myelin recovery in multiple sclerosis: the challenge of remyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Myelin alters the inflammatory phenotype of macrophages by activating PPARs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Immunoglobulins and complement in postmortem multiple sclerosis tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Homogeneity of active demyelinating lesions in established multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Axonal damage in acute multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Contribution of cortical lesion subtypes at 7T MRI to physical and cognitive performance in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Meningeal and cortical grey matter pathology in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Progressive multiple sclerosis: pathology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Elevated myeloperoxidase activity in white matter in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Immunopathology of secondary-progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The yin and yang of microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Microglial physiopathology: how to explain the dual role of microglia after acute neural disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Integration of the subarachnoid space and lymphatics: is it time to embrace a new concept of cerebrospinal fluid absorption?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Remyelination in the CNS: from biology to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Remyelination is extensive in a subset of multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Demyelination versus remyelination in progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

How mitochondria produce reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Iron in multiple sclerosis: roles in neurodegeneration and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Structural and functional features of central nervous system lymphatic vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Interferon-beta mechanisms of action in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Overlapping and distinct mechanisms of action of multiple sclerosis therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Molecular and biochemical pharmacology of mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Teriflunomide and its mechanism of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Endogenous and recombinant type I interferons and disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

T cell independent mechanism for copolymer-1-induced neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CD56bright natural killer (NK) cells: an important NK cell subset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CXCL13 antibody for the treatment of autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Effector and regulatory B cells: modulators of CD4+ T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Daclizumab therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Laquinimod therapy in multiple sclerosis: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Antigen-specific immunomodulation via altered peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Targeting the B7 family of co-stimulatory molecules: successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A new drug candidate (GEMSP) for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Border between natural product and drug: comparison of the related benzoquinones idebenone and coenzyme Q10

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Lipoic acid in multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The promise of minocycline in neurology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Nicotinic attenuation of central nervous system inflammation and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Phenytoin protects central axons in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Statins: mechanisms of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Anti-ergotypic immunoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Gilt required for RTL550-CYS-MOG to treat experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

RTL therapy for multiple sclerosis: a Phase I clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

T cell vaccination in multiple sclerosis: results of a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

T-cell vaccination in multiple sclerosis: update on clinical application and mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

T-cell vaccination in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Autologous T-cell vaccination for multiple sclerosis: a perspective on progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Oral tolerance: therapeutic implications for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

GEMSP: a new therapeutic approach to multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Stem cell therapy in multiple sclerosis: a future perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

High doses of biotin in chronic progressive multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Co-enzyme Q10 and idebenone use in Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Simvastatin improves final visual outcome in acute optic neuritis: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Lithium prevents and ameliorates experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Novel immunoregulatory properties of EGCG on reducing inflammation in EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Sun exposure and vitamin D are independent risk factors for CNS demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

Antibody responses following induction of antigen-specific tolerance with antigen-coupled cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1744666X.2016.1191351

10.1080/1744666X.2016.1191351

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference

PubMed ID

27191526